ADMA Biologics Inc.’s recently made public that its Director Grossman Jerrold B acquired Company’s shares for reported $0.48 million on Aug 30. In the deal valued at $3.71 per share,130,000 shares were bought. As a result of this transaction, Grossman Jerrold B now holds 443,265 shares worth roughly $ 1.61 million.
Then, KWON YOUNG bought 25,000 shares, generating $97,500 in total proceeds. Upon buying the shares at $3.90, the Director now owns 277,401 shares.
Before that, Fong Bryant sold 1,433,304 shares. ADMA Biologics Inc. shares valued at $5,544,737 were divested by the Director at a price of $3.87 per share. As a result of the transaction, Fong Bryant now holds 0 shares, worth roughly $0.0.
PT values the company’s stock at a premium of 27.2 to its Monday closing price.
Price Performance Review of ADMA
On Monday, ADMA Biologics Inc. [NASDAQ:ADMA] saw its stock fall -2.41% to $3.64. On the same session, the stock had its day’s lowest price of $3.615, but rose to a high of $3.84. Over the last five days, the stock has lost -4.71%. ADMA Biologics Inc. shares have fallen nearly -6.19% since the year began. Nevertheless, the stocks have risen 34.32% over the past one year. While a 52-week high of $4.65 was reached on 08/15/23, a 52-week low of $2.24 was recorded on 03/20/23. SMA at 50 days reached $3.92, while 200 days put it at $3.67. A total of 1.89 million shares were traded, compared to the trading of 4.7 million shares in the previous session.
Levels Of Support And Resistance For ADMA Stock
The 24-hour chart illustrates a support level at 3.56, which if violated will result in even more drops to 3.47. On the upside, there is a resistance level at 3.78. A further resistance level may holdings at 3.92. The Relative Strength Index (RSI) on the 14-day chart is 37.42, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.10, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 88.37%. Stochastics %K at 29.46% indicates the stock is a holding.
How much short interest is there in ADMA Biologics Inc.?
A steep rise in short interest was recorded in ADMA Biologics Inc. stocks on Aug 30, 2023, growing by 0.55 million shares to a total of 8.86 million shares. Yahoo Finance data shows the prior-month short interest on Jul 30, 2023 was 8.31 million shares. There was a rise of 6.21%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 4.13% of the overall stock float, the days-to-cover ratio (short ratio) rose to 3.04.
ADMA Biologics Inc. [ADMA] – Who Are The Largest Shareholders?
In filings from BlackRock Fund Advisors, it is revealed that the company now owns 14,813,612 shares, or roughly 6.59% of the outstanding ADMA shares. In other words, the investor’s shares have risen by 118,207 from its previous 13-F filing of 14695405.0. Additionally, The Vanguard Group, Inc. increased 5.43% of its stake after which the total value it holdings stand at $46,137,018. Over the last quarter, SSgA Funds Management, Inc. sold -2,474,686 shares of ADMA Biologics Inc., while Stonepine Capital Management LLC sold 1,131,631 shares. At present, D. E. Shaw & Co. LP is holding 8,173,817 shares valued at $31.47 million. Magnetar Financial LLC owned 6,035,538 shares of the company at the time of its most recent 13F filing, worth $23.24 million.
According to FactSet, ADMA Biologics Inc.’s share price will average $6.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 60.86 percent from its previous closing price of $3.73. Analysts expect ADMA Biologics Inc. stock to reach the higher price of $7.00, while the lowest price estimate is $5.00. However, 4 analysts have rated ADMA stock as a Buy in their predictions for 2023.